New radioactive drug aims to hit bone tumors while sparing marrow
NCT ID NCT06982222
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers will find the safest dose and watch for side effects and any signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tin-117m-DTPA (a radioactive compound that targets bone tumors)
- What this could lead to
- If it works, this could provide a new way to slow or shrink bone tumors while reducing damage to bone marrow.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety and dosing, not effectiveness. It may not work or may cause side effects like low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?